Drugs / Propylthiouracil
last change Jun 2024 re-read 2 minutes ago

Propylthiouracil

Small molecule targets DIO1, TPO via inhibition

Developed for
ischemic stroke · disease of orbital part of eye adnexa · endocrine exophthalmos · Graves disease · thyroid gland disorder
Investigated by
Maastricht University · European Commission

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) PROPYLTHIOURACIL 1947-07-28 fda.gov

Trials 2 · a red edge is where a trial was stopped

194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04776499 Mar 2021 → Feb 2022 Maastricht University Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05762146 Sep 2022 → Feb 2024 ischemic stroke Maastricht University Unknown No outcome recorded
Also used as a comparator or background therapy in 5 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 33 trials
Phase 3 NCT05118542 Comparator Jan 2019 → Jun 2020 Graves disease, atherosclerosis Indonesia University Completed No outcome recorded
Phase 3 NCT03066076 Comparator Mar 2017 → Feb 2019 Graves disease, endocrine exophthalmos Medical University of Vienna Unknown No outcome recorded
Phase 3 NCT01436994 Comparator Jul 2004 → Dec 2014 thyroid gland disorder Newcastle-upon-Tyne Hospitals NHS Trust Completed No outcome recorded
Phase 41 trial
Phase 4 NCT01056419 Comparator Jan 2009 → Jun 2010 disease of orbital part of eye adnexa Ankara University Unknown No outcome recorded
Phase not applicable1 trial
NCT00846755 Comparator Mar 2005 → Mar 2008 pregnancy disorder, thyroid gland disorder Ospedale V. Fazzi Completed No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as propylthiouracil “Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be...” NCT01436994
5

“Thiamazol, PropylthiouracilNCT03066076

NCT05118542

NCT01056419

NCT04776499

NCT05762146

Known as NSC-6498 ChEMBL registry synonym — accepted as the source's own label CHEMBL1518
Known as NSC-70461 ChEMBL registry synonym — accepted as the source's own label CHEMBL1518
Known as Propacil ChEMBL registry synonym — accepted as the source's own label CHEMBL1518
Known as Propiltiouracilo ChEMBL registry synonym — accepted as the source's own label CHEMBL1518
Known as Propylthiouracile ClinicalTrials.gov intervention name — accepted as the source's own label NCT00846755
Known as Prothyran ChEMBL registry synonym — accepted as the source's own label CHEMBL1518
Known as PTU “Anti-thyroid drugs (ATDs), such as propylthiouracil (PTU) and methimazole (MMI), are commonly used for GD treatment, and studies have suggested a link between these drugs and...” PMID 39355401 Jun 2024
Known as Thyreostat ii ChEMBL registry synonym — accepted as the source's own label CHEMBL1518
Action Inhibit “perphenazine, a typical antipsychotic, and propylthiouracil, a thyroid peroxidase inhibitor used for the treatment of hyperthyroidism, have previously been identified as...” NCT04776499
2

“Type I iodothyronine deiodinase (Type-I 5'-deiodinase) (DIOI) (Type 1 DI) (5DI) inhibitor” CHEMBL1518

“Thyroid peroxidase inhibitor” CHEMBL1518

Modality Small molecule CHEMBL1518
Route Oral orally administered combination therapy of riociguat, propylthiouracil, and perphenazine” NCT05762146
Target DIO1 “Type I iodothyronine deiodinase (Type-I 5'-deiodinase) (DIOI) (Type 1 DI) (5DI) inhibitor” CHEMBL1518
Target TPO “Thyroid peroxidase inhibitor” CHEMBL1518